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Abstract
Introduction: There is a reported association between sarcoidosis and malignancy. This is particularly true for lymphomas and is 
known as the sarcoidosis-lymphoma syndrome.
Case report: A 49 year old Caucasian female presented with mediastinal and axillary lymphadenopathy. An excisional axillary lymph 
node biopsy showed classical Hodgkin’s lymphoma, nodular sclerosis subtype. She received six cycles of conventional chemotherapy 
achieving a complete remission with no evidence of any lymphadenopathy on restaging imaging. However, one month after completion 
of chemotherapy, she developed new onset of progressive mediastinal lymphadenopathy. A mediastinoscopy and biopsy was performed 
showing noncaseating granulomata and the patient was diagnosed with a sarcoid reaction.
Conclusion: Sarcoidosis and sarcoid reactions must be considered in the differential diagnosis when assessing patients with persistent 
or enlargening masses after chemotherapy treatment for Hodgkin’s lymphoma, especially since this is associated with a better prog-
nosis. A tissue biopsy is essential prior to starting chemotherapy for presumed relapsed malignancy or persistent disease so as to avoid 
  inappropriate treatment.
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Brincker was the first to show a significantly higher 
than  expected  association  between  sarcoidosis  and 
lymphoma of all types; an approximately 11.5 fold 
increased risk.1 Lymphoma developing 1 to 2 years 
after  the  diagnosis  of  sarcoidosis  is  known  as  the 
sarcoidosis-lymphoma  syndrome.1  This  syndrome 
has been expanded to include patients with sarcoido-
sis who develop other hematologic malignancies and 
solid tumors such as lung and liver cancer and may 
be better known as the sarcoidosis-malignancy syn-
drome.2 In addition, this syndrome includes a subset 
of patients with hematologic malignancies and solid 
tumors who later develop sarcoidosis.2 Paraneoplas-
tic sarcoidosis develops concurrently with or within 
a year of the diagnosis of hematologic malignancy or 
solid tumor.2
Noncaseating granulomata of the regional lymph 
nodes or the organ of tumor involvement, without the 
systemic manifestations of sarcoidosis, are known as 
sarcoid reactions.2 As shown in this case report, sar-
coidosis and sarcoid reactions must be excluded by a 
tissue biopsy when assessing patients with persistent 
or enlargening masses after chemotherapy adminis-
tration for malignancies so as to avoid inappropriate 
treatment.
case Report
A 49 year old woman developed pruritus and progres-
sive axillary lymphadenopathy. Computed tomography 
(CT) and [18F] fluorodeoxyglucose-positron emission 
tomography (FDG PET) showed enlarged, FDG avid 
lymph nodes in the left supraclavicular, left axillary 
and mediastinal regions. An excisional left axillary 
lymph  node  biopsy  was  performed  which  showed 
classical  Hodgkin’s  lymphoma,  nodular    sclerosis 
  subtype.    Neoplastic  Reed-Sternberg  cells  were 
  positive for CD30 and CD15 but negative for CD20 
and CD3. A bone marrow biopsy was   normocellular 
without  evidence  of  Hodgkin’s  lymphoma.  Stage 
IIA Hodgkin’s lymphoma was diagnosed. Six cycles 
of doxorubicin, bleomycin, vinblastine, dacarbazine 
chemotherapy were initiated. After the fourth cycle 
of chemotherapy, a PET/CT scan showed no further 
FDG avidity or any evidence of lymphadenopathy. 
The  patient  achieved  a  complete  remission.  PET/
CT  performed  one  month  after  completion  of 
  chemotherapy,  showed  new  hilar  and  mediastinal 
lymphadenopathy with associated FDG avidity. There 
were  no  lung  parenchymal    abnormalities. A  medi-
astinoscopy with biopsy was performed. The lymph 
node biopsy showed the lymph node to be entirely 
replaced by confluent noncaseating epithelioid granu-
lomata with focal necrosis on hematoxylin and eosin 
(H&E) stain. No neoplastic Reed-Sternberg cells were 
noted. Gomori Methanamine Silver (GMS) and acid 
fast bacilli (AFB) stains were negative for fungal or 
  mycobacterial organisms. Three months after comple-
tion of chemotherapy, another PET/CT continued to 
show stable mediastinal and hilar lymphadenopathy 
with associated FDG avidity in these areas. Lymph 
nodes were less than 2 centimeters in largest diameter. 
The patient was asymptomatic without constitutional 
symptoms.  Physical  exam  revealed  no  peripheral 
lymphadenopathy or hepatosplenomegaly. The angio-
tensin  converting  enzyme  (ACE),  lactate  dehydro-
genase,  beta  2  microglobulin,  liver  function,  renal 
function, and calcium were normal. A complete blood 
count was remarkable only for lymphopenia. Human 
immunodeficiency virus (HIV) testing was negative. 
A second mediastinoscopy and biopsy again showed 
confluent  noncaseating  granulomata  of  the  lymph 
node suggestive of a sarcoid reaction (Figs. 1 and 2). 
GMS and AFB stains were negative for fungi and 
acid fast bacilli. There was no evidence of Hodgkin’s 
lymphoma on routine histology. Immunohistochem-
istry  staining  for  (cluster  of  differentiation)  CD30 
and  CD15 suggestive  of  neoplastic  Reed-Sternberg 
cells was absent. Flow cytometry of the lymph nodes 
was  unremarkable. A  bone  marrow  biopsy  showed 
Figure  1.  Mediastinal  lymph  node  (H&e,  200×)  showing  confluent 
  noncaseating granulomata.
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change. Two years after completion of chemotherapy 
the patient remained asymptomatic with persistent but 
stable mediastinal and hilar lymphadenopathy on PET/
CT and no evidence of relapsed Hodgkin’s lymphoma 
or systemic manifestations of sarcoidosis.
Discussion
The  relationship  between  sarcoidosis  and 
malignancy is a controversial subject. The increased 
incidence  of  malignancy  in  patients  with  sarcoi-
dosis  was  first  described  by  Brincker.1  Between 
1962 and 1972, 48 out of 2544 patients enrolled in 
the  Danish  sarcoidosis  registry  developed  malig-
nant  tumors  including  lymphoid  and  solid  tumors 
compared to only 33 malignant tumors on the basis 
of  age  and  gender  specific  incidences  in  the  con-
trol  group.1  Lymphomas  developed  in  17  patients; 
8 with Hodgkin’s lymphoma, 9 with non-Hodgkin’s 
lymphoma, chronic lymphocytic leukemia or multi-
ple myeloma. Patients with chronic active sarcoidosis 
had an 11.5 fold increased incidence of lymphoma.1 
The same authors, after a review of a cohort of 18% 
of the Danish population, estimated the incidence of 
lymphoma of all types in patients with sarcoid to be 
5.5 fold higher than   expected.3 The only other malig-
nancy occurring with higher frequency in the same 
population  was  lung  cancer  which  had  a  3.5  fold 
higher incidence in patients with sarcoid than in the 
general population.3 Brincker postulated the existence 
of a sarcoidosis-lymphoma syndrome characterized 
by  the  development  of  a  lymphoid  neoplasm  one 
to two years after a diagnosis of sarcoidosis. These 
patients also had a median age of onset of   sarcoidosis 
of more than 40 years which is at least 10 years older 
than  that  of  unselected  patients  with  sarcoidosis. 
Hodgkin’s lymphoma was found to occur more fre-
quently than other types of   lymphoma.2 Hodgkin’s 
and non-Hodgkin’s lymphoma occurred earlier than 
chronic lymphocytic leukemia and paraproteinemias, 
probably  reflecting  the  differing  natural  history  of 
these conditions.3 In another sarcoid registry study, 
Reich found no instances of sarcoidosis accompany-
ing Hodgkin’s lymphoma using the linkage criteria 
previously reported (associated malignancy occurring 
1 to 2 years after the diagnosis of sarcoidosis and with 
a median age of onset of sarcoidosis at least 10 years 
olderthan that of unselected patients with sarcoido-
sis).4 However, more recently, in the largest study to 
be conducted on this topic, involving 10,037 patients 
hospitalized for sarcoidosis in Sweden between 1964 
and 2004, there was an overall 40% excess incidence 
of cancer and the risk was still above unity (1.18) 
when analyzing only those cancers diagnosed after 
one year of follow up.5 Squamous cell carcinomas of 
the  skin,  non-Hodgkin’s  lymphoma  and  leukemias 
accounted for the majority of the cancers.
Sarcoidosis is known to be associated with activa-
tion of CD4+ T cells and down regulation of CD8+ T 
cells leading to dysfunction in the immunoregulatory 
pathways and the formation of noncaseating granu-
lomata  and  lymphoid  neoplasms.6  Sarcoidosis  and 
Hodgkin’s disease have several immunologic simi-
larities; both are characterized by cutaneous anergy, 
peripheral lymphopenia, and prominent tissue infil-
tration of helper T cells. Another theory, postulates 
that clinical sarcoid is a generalized cell mediated 
immune response to tumor antigens representing the 
systemic  counterpart  of  the  localized  noncaseating 
granulomata present within tumors.2,6 In addition to 
the possible mechanisms already discussed, immu-
nosuppression from chemotherapy or drug reaction 
are other possibilities.2 For example, bleomycin con-
centrates more in the lymph nodes, skin and lung tis-
sue than other agents and these are the tissues with 
a predilection for developing sarcoidosis.2,6 However 
sarcoidosis can occur after malignancy without the 
administration of chemotherapy.10
Usually  sarcoidosis  precedes  the  development 
of  lymphomas.7  On  occasion,  lymphoma  can  also 
Figure 2. Mediastinal lymph node (H&e, 400×) showing noncaseating 
granulomata.
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Suen et al analyzed 6 cases of patients with biopsy 
proven  malignancy  (ovarian  cancer,  breast  cancer, 
Hodgkin’s  disease,  non-Hodgkin’s  lymphoma  and 
T  cell  lymphoma)  who  developed  biopsy  proven 
sarcoidosis on average 9 months after the onset of 
malignancy with or without the prior administration 
of   chemotherapy.10 The sarcoidosis-lymphoma syn-
drome has been expanded to include the diagnosis of 
other hematological malignancies and solid tumors 
occurring one to two years after or before the diag-
nosis of sarcoidosis and may be better known as the 
sarcoidosis-malignancy syndrome.2 The diagnosis of 
sarcoidosis concurrently with or within one year of 
the diagnosis of cancer is known as paraneoplastic 
sarcoidosis.2
The diagnosis of sarcoidosis, a multisystem granu-
lomatous disorder of unknown etiology, is based on a 
combination of clinical, radiological and histological 
findings.11 The PET scan shows FDG avidity in lymph 
nodes involved by sarcoidosis indicative of immune 
activation and resultant metabolic activity.12 Features 
supporting a diagnosis of sarcoidosis include clinical 
findings (fever, cough, dyspnea, parotid gland enlarge-
ment, arthralgias, arthritis, peripheral lymphadenopa-
thy, cranial nerve palsies, meningitis), biochemical 
tests (such as hypercalcemia and lymphopenia) and 
findings  of  noncaseating  granulomata  on  tissue 
biopsy.11 Infections need to be excluded, in particu-
lar mycobacterial and fungal infections, as these can 
morphologically and clinically mimic sarcoidosis.11 
The angiotensin converting enzyme (ACE) level is 
elevated in only two thirds of cases of sarcoidosis. 
The Kveim-Siltzbach test, which is positive in 70% 
of cases of sarcoidosis, is no longer in general use 
and has been supplanted by transbronchial biopsy and 
mediastinoscopy with lymph node biopsy.11 The his-
tologic hallmark of sarcoidosis, noncaseating granu-
lomata, can be seen in regional draining lymph nodes 
or the organ of tumor involvement and are referred to 
as sarcoid reactions in patients who do not have all the 
criteria for systemic sarcoidosis.13 Sarcoid reactions 
can occur in 4.4% of carcinomas, 13.8% of Hodgkin’s 
lymphoma and 7.3% of non-Hodgkin’s lymphomas.13 
These  local  sarcoid  reactions  can  generalize  over 
time leading to difficulty in diagnosing tumor related 
sarcoid  reactions  versus  systemic    sarcoidosis.  The 
presumed  mechanism  for  the    formation  of  sarcoid 
reactions is an induced T cell mediated host response 
to soluble tumor antigens shed by the tumor cells or 
released during tumor necrosis.14 Sarcoid reactions 
are a positive prognostic indicator in patients with 
Hodgkin’s disease as well as gastric cancer as these 
patients have a longer relapse free survival and over-
all survival.2,14
In  this  article,  the  patient  with  Hodgkin’s  lym-
phoma had new onset of progressive mediastinal and 
hilar  lymphadenopathy  after  achieving  a  complete 
response with chemotherapy. The mediastinal lymph 
node biopsies, repeated on two occasions, 1 month 
and  3  months  after  completion  of  chemotherapy, 
showed confluent noncaseating granulomata without 
evidence of neoplastic Reed-Sternberg cells to sug-
gest relapsed Hodgkin’s lymphoma. There was also 
no evidence of mycobacterial or fungal infection. The 
patient had no constitutional symptoms. This patient 
was diagnosed with a sarcoid reaction. The patient 
has been followed for 2 years after completion of 
chemotherapy with stable but persistent mediastinal 
and hilar lymphadenopathy and without recurrence of 
Hodgkin’s lymphoma or manifestations of systemic 
sarcoidosis.
The differential diagnosis of a persistent or enlargen-
ing mass after chemotherapy treatment for Hodgkin’s 
lymphoma includes fibrosis, thymic hyperplasia and 
persistent or relapsed lymphoma. To this list must 
be added sarcoidosis and sarcoid reactions, as high-
lighted by this article. There should be an awareness 
of the possibility of sarcoid reactions in the setting of 
a persistent or enlargening mass after chemotherapy, 
especially  since  these  are  associated  with  a  better 
prognosis. A tissue biopsy is essential prior to starting 
chemotherapy for a presumed relapse or treatment 
failure in patients with Hodgkin lymphoma so as to 
avoid inappropriate therapy.
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